H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating on August 15.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Robert Burns has given his Hold rating due to a combination of factors surrounding Atara Biotherapeutics. The company’s recent developments with tab-cel, particularly the FDA’s assignment of a PDUFA date for January 2026, are significant. However, despite the potential for a $40 million milestone payment and future royalties if tab-cel is approved, Burns does not see a compelling investment case at this time.
Financially, Atara reported better-than-expected results for the second quarter of 2025, with net earnings surpassing previous forecasts. Despite these positive financials, Burns maintains a neutral stance, citing the lack of a compelling investment case and the absence of a price target for ATRA shares. Additionally, the risks associated with the approval process and other pipeline candidates contribute to the Hold rating.
In another report released on August 15, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $12.00 price target.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is neutral on the stock.